Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open-Label, Daily Dose, 2-sequence, 2-way Crossover Pharmacodynamic and Pharmacokinetic Study of BiDil XR Capsules and Commercial BiDil Tablets in Self-identified Black Patients, Who Are Slow Acetylators, With Heart Failure

NCT02522208 is registered in ClinicalTrials.gov with Arbor Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02522208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02522208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open-Label, Daily Dose, 2-sequence, 2-way Crossover Pharmacodynamic and Pharmacokinetic Study of BiDil XR Capsules and Commercial BiDil Tablets in Self-identified Black Patients, Who Are Slow Acetylators, With Heart Failure
Lead sponsor
Arbor Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2015
Completion date
April 30, 2016
Enrollment
12 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure